Robert J Hayashi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2940863/publications.pdf

Version: 2024-02-01

137	7,112 citations	42	82
papers		h-index	g-index
139	139	139	9119
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The Central Role of CD4+ T Cells in the Antitumor Immune Response. Journal of Experimental Medicine, 1998, 188, 2357-2368.	4.2	1,194
2	Evaluating Pediatric Brain Tumor Cellularity with Diffusion-Tensor Imaging. American Journal of Roentgenology, 2001, 177, 449-454.	1.0	355
3	Increasing Incidence of Chronic Graft-versus-Host Disease inÂAllogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2015, 21, 266-274.	2.0	331
4	Childhood Cancer Survivors' Knowledge About Their Past Diagnosis and Treatment. JAMA - Journal of the American Medical Association, 2002, 287, 1832.	3.8	316
5	Cyclophosphamide Plus Topotecan in Children With Recurrent or Refractory Solid Tumors: A Pediatric Oncology Group Phase II Study. Journal of Clinical Oncology, 2001, 19, 3463-3469.	0.8	293
6	The genomic landscape of juvenile myelomonocytic leukemia. Nature Genetics, 2015, 47, 1326-1333.	9.4	233
7	Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 66-97.	2.3	206
8	In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression Journal of Experimental Medicine, 1994, 179, 1215-1224.	4.2	184
9	Adolescent and Young Adult Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1112-1150.	2.3	173
10	Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. Journal of Clinical Oncology, 2018, 36, 2926-2934.	0.8	164
11	Low-Dose Chemotherapy and Rituximab for Posttransplant Lymphoproliferative Disease (PTLD): A Children's Oncology Group Report. American Journal of Transplantation, 2012, 12, 3069-3075.	2.6	156
12	Hematopoietic Stem Cell Transplantation for Refractory or Recurrent Non-Hodgkin Lymphoma in Children and Adolescents. Biology of Blood and Marrow Transplantation, 2010, 16, 223-230.	2.0	144
13	Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplantation, 2015, 50, 1013-1023.	1.3	136
14	Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2020, 38, 3282-3293.	0.8	136
15	A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplantation, 2005, 35, 345-352.	1.3	128
16	Impact of radiation and chemotherapy on risk of dental abnormalities. Cancer, 2009, 115, 5817-5827.	2.0	117
17	Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. American Journal of Hematology, 2015, 90, 1093-1098.	2.0	109
18	Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplantation, 2001, 27, 1059-1064.	1.3	103

#	Article	IF	CITATIONS
19	Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Transplantation, 2008, 42, 175-180.	1.3	97
20	Adolescent and Young Adult Oncology, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 21-32.	2.3	97
21	Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: The Pediatric Blood and Marrow Transplant Consortium Experience (PBMTC) 1996–2003. Bone Marrow Transplantation, 2005, 35, 361-367.	1.3	96
22	Posttransplantation Lymphoproliferative Disorder in Children: Clinical, Histopathologic, and Imaging Features. Radiology, 2000, 217, 16-25.	3.6	87
23	Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genetics in Medicine, 2005, 7, 143-146.	1.1	87
24	Cognitive, behaviour, and academic functioning in adolescent and young adult survivors of childhood acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study. Lancet Psychiatry,the, 2016, 3, 965-972.	3.7	82
25	Improved survival after acute graft- <i>versus</i> -host disease diagnosis in the modern era. Haematologica, 2017, 102, 958-966.	1.7	79
26	Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood, 2008, 111, 4014-4021.	0.6	76
27	Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplantation, 2018, 53, 535-555.	1.3	75
28	High Incidence of Posttransplant Lymphoproliferative Disease in Pediatric Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 1252-1255.	2.5	74
29	Posttransplant Lymphoproliferative Disease in Children: Correlation of Histology to Clinical Behavior. The American Journal of Pediatric Hematology/oncology, 2001, 23, 14-18.	1.3	72
30	Hearing Loss in Pediatric Oncology Patients Receiving Carboplatin-containing Regimens. Journal of Pediatric Hematology/Oncology, 2008, 30, 130-134.	0.3	65
31	A Comparison of Walking <i>versus </i> Stretching Exercises to Reduce the Incidence of Preeclampsia: A Randomized Clinical Trial. Hypertension in Pregnancy, 2008, 27, 113-130.	0.5	57
32	Physical impairment and social adaptation in adult survivors of childhood and adolescent rhabdomyosarcoma: a report from the Childhood Cancer Survivors Study. Psycho-Oncology, 2007, 16, 26-37.	1.0	54
33	COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy Journal of Clinical Oncology, 2018, 36, 10500-10500.	0.8	54
34	Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2014, 20, 1777-1784.	2.0	50
35	Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2015, 21, 151-158.	2.0	49
36	Late Onset Hearing Loss: A Significant Complication of Cancer Survivors Treated With Cisplatin Containing Chemotherapy Regimens. Journal of Pediatric Hematology/Oncology, 2010, 32, 119-123.	0.3	48

#	Article	IF	CITATIONS
37	Differential effects of radiotherapy on growth and endocrine function among acute leukemia survivors: A childhood cancer survivor study report. Pediatric Blood and Cancer, 2013, 60, 110-115.	0.8	48
38	The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2015, 21, 1746-1753.	2.0	48
39	Cytomegalovirus viremia associated with death or retransplantation in pediatric lung-transplant recipients. Transplantation, 2003, 75, 1538-1543.	0.5	47
40	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leukemia Research, 2018, 74, 130-136.	0.4	47
41	A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplantation, 2015, 50, 1416-1423.	1.3	45
42	Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. Journal of Clinical Oncology, 2022, 40, 2106-2118.	0.8	45
43	Longâ€term outcomes among 2â€year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large bâ€cell lymphoma. Cancer, 2018, 124, 816-825.	2.0	44
44	Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders. Biology of Blood and Marrow Transplantation, 2016, 22, 1467-1472.	2.0	43
45	Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. 2018. 24. 228-241.	2.0	43
46	Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434. Journal of Clinical Oncology, 2020, 38, 3062-3070.	0.8	42
47	Second malignancies after autologous hematopoietic cell transplantation in children. Bone Marrow Transplantation, 2013, 48, 363-368.	1.3	39
48	A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood. Neuro-Oncology, 2013, 15, 783-787.	0.6	38
49	Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age. Biology of Blood and Marrow Transplantation, 2017, 23, 1327-1334.	2.0	38
50	Comparative Analysis of Calcineurin Inhibitor–Based Methotrexate and Mycophenolate Mofetil–Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 73-85.	2.0	35
51	Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation. Pediatric Blood and Cancer, 2010, 54, 291-298.	0.8	33
52	Regulation of biogenic amine methyltransferases by glucocorticoids via s-adenosylmethionine and its metabolizing enzymes, methionine adenosyltransferase and s-adenosylhomocysteine hydrolase. Brain Research, 1985, 330, 209-216.	1.1	32
53	Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in pediatric and young adult lung transplant recipients. Pediatric Transplantation, 2007, 11, 312-318.	0.5	31
54	Chest radiography as a predictor of outcome in posttransplantation lymphoproliferative disorder in lung allograft recipients American Journal of Roentgenology, 1998, 171, 375-382.	1.0	29

#	Article	IF	CITATIONS
55	Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation. Journal of the American Academy of Dermatology, 2008, 58, 575-578.	0.6	29
56	Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. Biology of Blood and Marrow Transplantation, 2019, 25, 301-306.	2.0	27
57	Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2015, 21, 2154-2159.	2.0	25
58	Phase 1 Study of Paclitaxel Administered Twice Weekly to Children With Refractory Solid Tumors: A Pediatric Oncology Group Study. Journal of Pediatric Hematology/Oncology, 2003, 25, 539-542.	0.3	23
59	Neurocognitive Outcomes and School Performance in Solid Tumor Cancer Survivors Lacking Therapy to the Central Nervous System. Journal of Personalized Medicine, 2015, 5, 83-90.	1.1	23
60	Late Effects of Childhood Cancer, Participation, and Quality of Life of Adolescents. OTJR Occupation, Participation and Health, 2009, 29, 116-124.	0.4	21
61	Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen. Bone Marrow Transplantation, 2008, 41, 349-353.	1.3	20
62	Participation and Self-Management Strategies of Young Adult Childhood Cancer Survivors. OTJR Occupation, Participation and Health, 2013, 33, 21-30.	0.4	19
63	Anti-CD20 Monoclonal Antibody (rituximab) for Refractory PTLD after Pediatric Solid Organ Transplantation: Multicenter Experience from a Registry and from a Prospective Clinical Trial Blood, 2004, 104, 746-746.	0.6	19
64	Otolaryngological manifestations of posttransplant lymphoproliferative disorder in pediatric thoracic transplant patients. International Journal of Pediatric Otorhinolaryngology, 2006, 70, 303-310.	0.4	18
65	Outcomes following autologous hematopoietic stem cell transplant for patients with relapsed Wilms' tumor: a CIBMTR retrospective analysis. Bone Marrow Transplantation, 2017, 52, 1549-1555.	1.3	17
66	Late Health Outcomes After Contemporary Lymphome Malin de Burkitt Therapy for Mature B-Cell Non-Hodgkin Lymphoma: A Report From the Childhood Cancer Survivor Study. Journal of Clinical Oncology, 2019, 37, 2556-2570.	0.8	17
67	Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Advances, 2020, 4, 2084-2094.	2.5	14
68	Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2015, 21, 1776-1782.	2.0	13
69	Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1523-1530.	2.0	13
70	Knowledge and perceptions of infertility in female cancer survivors and their parents. Supportive Care in Cancer, 2018, 26, 2433-2439.	1.0	13
71	Comparison of total body irradiation <i>versus</i> non-total body irradiation containing regimens for de novo acute myeloid leukemia in children. Haematologica, 2021, 106, 1839-1845.	1.7	13
72	Increased complications of chronic erythrocytapheresis compared with manual exchange transfusions in children and adolescents with sickle cell disease. Pediatric Blood and Cancer, 2017, 64, e26635.	0.8	12

#	Article	IF	Citations
73	Challenges Evaluating Chemotherapy-Induced Peripheral Neuropathy in Childhood Cancer Survivors. Journal of Pediatric Oncology Nursing, 2017, 34, 106-114.	1.5	12
74	Clostridioides difficile Infections in Inpatient Pediatric Oncology Patients: A Cohort Study Evaluating Risk Factors and Associated Outcomes. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 302-308.	0.6	12
75	Capizzi-Style Methotrexate with Pegasparagase (C-MTX) Is Superior to High-Dose Methotrexate (HDMTX) in T-Lineage Acute Lymphoblastic Leukemia (T-ALL): Results from Children's Oncology Group (COG) AALL0434. Blood, 2015, 126, 794-794.	0.6	12
76	Alemtuzumab based reduced intensity transplantation for pediatric severe aplastic anemia. Pediatric Blood and Cancer, 2015, 62, 1270-1276.	0.8	11
77	Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin. Biology of Blood and Marrow Transplantation, 2015, 21, 1321-1325.	2.0	11
78	Early outcomes after allogeneic hematopoietic SCT in pediatric patients with hematologic malignancies following single fraction TBI. Bone Marrow Transplantation, 2009, 43, 307-314.	1.3	10
79	Determining the prevalence of vestibular screening failures in pediatric cancer patients whose therapies include radiation to the head/neck and platinâ€based therapies: A pilot study. Pediatric Blood and Cancer, 2018, 65, e26992.	0.8	10
80	Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients. Biology of Blood and Marrow Transplantation, 2019, 25, 556-561.	2.0	10
81	Cisplatin Ototoxicity: Examination of the Impact of Dosing, Infusion Times, and Schedules In Pediatric Cancer Patients. Frontiers in Oncology, 2021, 11, 673080.	1.3	10
82	Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. Transplantation and Cellular Therapy, 2021, 27, 679.e1-679.e8.	0.6	10
83	Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231. Blood, 2020, 136, 11-12.	0.6	10
84	Isolated CNS Relapse Following Stem Cell Transplantation for Juvenile Myelomonocytic Leukemia. Journal of Pediatric Hematology/Oncology, 2003, 25, 910-913.	0.3	9
85	Granulomatous dermatitis secondary to vemurafenib in a child with Langerhans cell histiocytosis. Pediatric Dermatology, 2018, 35, e402-e403.	0.5	9
86	Psychological, educational, and social late effects in adolescent survivors of Wilms tumor: A report from the Childhood Cancer Survivor Study. Psycho-Oncology, 2021, 30, 349-360.	1.0	9
87	Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1105-1123.	2.3	9
88	Unique CD4+ T cells in TCR $\hat{l}\pm$ chain-deficient class I MHC-restricted TCR transgenic mice: role in a superantigen-mediated disease process. International Immunology, 1999, 11, 1581-1590.	1.8	8
89	Asymmetric sensorineural hearing loss is a risk factor for lateâ€onset hearing loss in pediatric cancer survivors following cisplatin treatment. Pediatric Blood and Cancer, 2019, 66, e27494.	0.8	8
90	Prevalence of Ototoxicity Following Hematopoietic Stem Cell Transplantation in Pediatric Patients. Biology of Blood and Marrow Transplantation, 2020, 26, 107-113.	2.0	8

#	Article	IF	CITATIONS
91	Longitudinal Evaluation of Neuromuscular Dysfunction in Long-term Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1536-1545.	1.1	8
92	Need for Population Specific Validation of a Portable Metabolic Testing System: A Case of Sedentary Pregnant Women. Journal of Nursing Measurement, 2005, 13, 207-218.	0.2	7
93	Development of Electronic Chemotherapy Roadmaps for Pediatric Oncology Patients. Journal of Pediatric Oncology Nursing, 2018, 35, 314-319.	1.5	7
94	Prevalence and nature of hearing loss in a cohort of children with sickle cell disease. Pediatric Blood and Cancer, 2019, 66, e27457.	0.8	7
95	Late Toxicity of a Novel Allogeneic Stem Cell Transplant Using Single Fraction Total Body Irradiation for Hematologic Malignancies in Children. Journal of Pediatric Hematology/Oncology, 2015, 37, e94-e101.	0.3	6
96	Adolescent and young adult cancer survivorship: The new frontier for investigation. Cancer, 2019, 125, 1976-1978.	2.0	5
97	Considerations in Preparative Regimen Selection to Minimize Rejection in Pediatric Hematopoietic Transplantation in Non-Malignant Diseases. Frontiers in Immunology, 2020, 11, 567423.	2.2	5
98	Identification of Igh-C-linked determinants on suppressor T cell hybrids and factors specific for L-glutamic acid60-L-alanine30-L-tyrosine10 (GAT) Journal of Experimental Medicine, 1985, 162, 1044-1059.	4.2	4
99	Cytogenetic abnormalities in two cases of neuroblastoma. Cancer Genetics and Cytogenetics, 1994, 74, 30-34.	1.0	4
100	Requirement of high-affinity IL-2–IL-2R interaction for T cell anergy induction. International Immunology, 2006, 18, 645-651.	1.8	4
101	Paediatric oncology simulation training for resident education. BMJ Simulation and Technology Enhanced Learning, 2019, 5, 155-160.	0.7	4
102	Adolescent survivors' information needs for transitions to postsecondary education and employment. Pediatric Blood and Cancer, 2019, 66, e27547.	0.8	3
103	Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma. Blood Advances, 2021, 5, 2890-2900.	2.5	3
104	Reduced Intensity Conditioning Therapy Using Campath -1H Is Successful for Stem Cell Transplantation in Non-Malignant Disorders Blood, 2004, 104, 1823-1823.	0.6	3
105	Patient and Parent Decision-Making in the Setting of Chemotherapy-Induced Sensorineural Hearing Loss. Ear and Hearing, 2020, 41, 1684-1691.	1.0	3
106	Treatment of small and medium retinoblastoma tumors with Iris diode laser. European Journal of Ophthalmology, 2021, 31, 112067212199139.	0.7	2
107	Successful treatment of CNS involvement in a patient with widely disseminated PTLD through the addition of intrathecal methotrexate to standard therapy. Pediatric Blood and Cancer, 2021, 68, e29236.	0.8	2
108	Children's Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL). Blood, 2018, 132, 1000-1000.	0.6	2

#	Article	IF	Citations
109	Neurocognitive, emotional, and quality of life outcomes in long-term survivors of rhabdomyosarcoma: A report from the Childhood Cancer Survivor Study (CCSS) Journal of Clinical Oncology, 2015, 33, 10072-10072.	0.8	2
110	Prevalence of hearing screening failures in lowâ€risk childhood cancer survivors. Pediatric Blood and Cancer, 2022, 69, e29437.	0.8	2
111	Immune Reconstitution Following Reduced Intensity Stem Cell Transplantation for Non-Malignant Disorders in Children. Biology of Blood and Marrow Transplantation, 2013, 19, S200.	2.0	1
112	Reduced Intensity Transplantation for Inherited Bone Marrow Failure Syndromes. Biology of Blood and Marrow Transplantation, 2015, 21, S230.	2.0	1
113	Special Therapy and Psychosocial Needs Identified in a Multidisciplinary Cancer Predisposition Syndrome Clinic. Journal of Pediatric Hematology/Oncology, 2019, 41, 133-136.	0.3	1
114	Chronic Manual Exchange Transfusions Compared with Erythrocytapheresis in Children and Teens with Sickle Cell Disease. Blood, 2014, 124, 4927-4927.	0.6	1
115	Cognitive, Behavior and Academic Problems in Adolescent Survivors of Childhood Acute Lymphoblastic Leukemia (ALL): A Report from the Childhood Cancer Survivor Study. Blood, 2015, 126, 877-877.	0.6	1
116	Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2021, 138, 3487-3487.	0.6	1
117	Neurocognitive Function in Pediatric Stem Cell Transplant Recipients Following Low Dose Single Fraction Total Body Radiation and Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2013, 19, S217.	2.0	0
118	Long-Term Survival and Late Effects Among 1-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation (2nd Allo HCT) for Relapsed Acute Leukemia and Myelodysplastic Syndrome: A Report from the Cibmtr. Biology of Blood and Marrow Transplantation, 2014, 20, S64.	2.0	0
119	Survival and Late Effects of Children Undergoing Myeloablative Allogeneic HCT at Less Than Three Years of Age: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2016, 22, S28-S29.	2.0	0
120	Response to: "Technology and Long-Term Health-Related Quality-of-Life Outcomes in Children with Nonmalignant Disorders after Reduced-Intensity Conditioning and Stem Cell Transplantationâ€. Biology of Blood and Marrow Transplantation, 2016, 22, 1734.	2.0	0
121	15. Genomic and clinical characterization of early T-cell precursor acute lymphoblastic lymphoma (ETP-LBL). Cancer Genetics, 2018, 226-227, 41.	0.2	0
122	Scope of hearing loss in Beckwith–Wiedemann syndrome and hemihypertrophy. American Journal of Medical Genetics, Part A, 2019, 179, 2307-2310.	0.7	0
123	Targeted gene expression classifier identifies pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients at high risk for end induction minimal residual disease positivity Journal of Clinical Oncology, 2021, 39, 10002-10002.	0.8	0
124	Editorial: Immunological Challenges Following Pediatric Hematopoietic Transplantation. Frontiers in Immunology, 2021, 12, 732261.	2.2	0
125	Cognition and Quality of Life Among Survivors of Pediatric Non-CNS Cancers Receiving Ototoxic Therapy. American Journal of Occupational Therapy, 2021, 75, 7512500011p1-7512500011p1.	0.1	0
126	Developmental Delay and School Performance Among Retinoblastoma Survivors. American Journal of Ophthalmology, 2021, 229, 266-273.	1.7	0

#	Article	IF	CITATIONS
127	Cause-Specific Mortality and Second Cancer Incidence after Non-Hodgkin Lymphoma: A Report from the Childhood Cancer Survivor Study Blood, 2007, 110, 3579-3579.	0.6	0
128	Pharmacokinetics of Alemtuzumab Used as Conditioning Agent in Reduced Intensity Transplantation for Pediatric Non-Malignant Disorders Blood, 2008, 112, 3290-3290.	0.6	0
129	Designated Donor Program Enrollment Does Not Affect Red Blood Cell Alloimmunization Rates in Children with Sickle Cell Disease on Chronic Transfusion Therapy. Blood, 2014, 124, 4291-4291.	0.6	0
130	Development of a Division-Based, Longitudinal Palliative Care Registry for Pediatric Oncology and Stem Cell Transplant Patients. Pediatrics, 2016, 137, 311A-311A.	1.0	0
131	Estimated Late Health Outcomes in Children Newly Diagnosed with Mature B-Cell Non-Hodgkin Lymphoma Treated with Contemporary LMB Chemotherapy Based upon Similarly Treated Participants in the Childhood Cancer Survivor Study (CCSS). Blood, 2016, 128, 3609-3609.	0.6	0
132	Psychological and educational outcomes among adolescent survivors of wilms tumor: A report from the Childhood Cancer Survivor study Journal of Clinical Oncology, 2017, 35, 10049-10049.	0.8	0
133	Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in pediatric T-cell acute lymphoblastic leukemia Journal of Clinical Oncology, 2019, 37, 10033-10033.	0.8	0
134	Neuromuscular dysfunction and associated health/socioeconomic outcomes: A report from the Childhood Cancer Survivor Study (CCSS) Journal of Clinical Oncology, 2020, 38, 10546-10546.	0.8	0
135	Case 28: Blueberry Muffin Rash and Respiratory Distress in a Late-Preterm Infant. , 2018, , 201-208.		0
136	Outcomes of patients with unilateral retinoblastoma: A report from the RIVERBOAT Consortium Journal of Clinical Oncology, 2022, 40, 10046-10046.	0.8	0
137	Outcomes of patients with bilateral retinoblastoma: A report from the RIVERBOAT Consortium Journal of Clinical Oncology, 2022, 40, 10045-10045.	0.8	0